Table 2:
Frequency of Esophaaectomv Marqin Positivity bv Sample Characteristics
| Negative Margin | Positive Margin | p-value* | |
|---|---|---|---|
| N (%) | |||
| Total Cases | 26,924 (90.63%) | 2,782 (9.37%) | |
| Age | |||
| <55 | 5,578(91.44%) | 522 (8.56%) | <0.001 |
| 55–64 | 9,423(91.61%) | 863 (8.39%) | |
| 65–74 | 8,671 (90.95%) | 863 (9.05%) | |
| ≥75 | 3,252 (85.90%) | 534(14.10%) | |
| Sex | |||
| Male | 22,386 (90.66%) | 2,305 (9.34%) | 0.696 |
| Female | 4,538(90.49%) | 477(9.51%) | |
| Race | |||
| White | 24,276 (90.82%) | 2,455 (9.18%) | 0.004 |
| Black | 1,092(88.28%) | 145(11.72%) | |
| Hispanic | 716 (88.50%) | 93 (11.50%) | |
| Other | 840 (90.42%) | 89 (9.58%) | |
| Insurance Status | |||
| Medicaid/Medicare | 12,719(89.33%) | 1,519(10.67%) | <0.001 |
| Private | 12,772 (92.14%) | 1,090 (7.86%) | |
| Other Government | 442 (90.39%) | 47 (9.61%) | |
| Uninsured | 547 (87.94%) | 75 (12.06%) | |
| Charlson-Deyo Index | |||
| 0 | 19,724 (90.75%) | 2,010 (9.25%) | 0.001 |
| 1 | 5,706 (90.95%) | 568 (9.05%) | |
| 2 | 1,164(88.52%) | 151 (11.48%) | |
| ≥3 | 330 (86.16%) | 53 (13.84%) | |
| Median Zip Code Income | |||
| <38,000 | 3,949(89.69%) | 454(10.31%) | 0.039 |
| 38,000–47,999 | 6,557(90.84%) | 661 (9.16%) | |
| 48,000–62,999 | 7,763 (90.59%) | 786(9.41%) | |
| >63,000 | 8,472(91.19%) | 818(8.81%) | |
| Quartile of Distance to Hospital (miles) | |||
| 1 (<1–7.3) | 6,671 (89.92%) | 748(10.08%) | <0.001 |
| 2(7.4–18.5) | 6,564 (90.46%) | 692 (9.54%) | |
| 3(18.6–49.8) | 6,596(90.57%) | 687 (9.43%) | |
| 4 (≥49.9) | 6,723(91.87%) | 595(8.13%) | |
| Facility Type | |||
| Academic/Research | 14,601 (91.40%) | 1,373 (8.60%) | <0.001 |
| Integrated Network Cancer Program | 2,710(90.76%) | 276 (9.24%) | |
| Comprehensive Community Cancer Program | 7,965(89.85%) | 900(10.15%) | |
| Community Cancer Program | 1,275 (87.51%) | 182 (12.49%) | |
| Hospital Location | |||
| Metro | 20,910(90.75%) | 2,132 (9.25%) | 0.444 |
| Urban | 4,475(90.31%) | 480 (9.69%) | |
| Rural | 582 (91.65%) | 53 (8.35%) | |
| Histologic Morphology | |||
| Adenocarcinoma | 21,741 (90.97%) | 2,158 (9.03%) | <0.001 |
| Squamous Cell Carcinoma | 4,293(88.81%) | 541 (11.19%) | |
| Carcinoma NOS | 890 (91.47%) | 83 (8.53%) | |
| Tumor Location | |||
| Upper Third | 451 (81.26%) | 104(18.74%) | <0.001 |
| Middle Third | 2,877 (89.63%) | 333(10.37%) | |
| Lower Third | 20,554 (91.37%) | 1,941 (8.63%) | |
| Overlapping Sites/NOS | 3,042 (88.28%) | 404(11.72%) | |
| Clinical T Stage | |||
| Tis | 849 (90.90%) | 85 (9.10%) | <0.001 |
| T1 | 5,021 (90.91%) | 502 (9.09%) | |
| T2 | 3,966 (92.86%) | 305 (7.14%) | |
| T3 | 10,224 (92.07%) | 880 (7.93%) | |
| T4 | 507 (85.07%) | 89 (14.93%) | |
| Clinical N Stage | |||
| NO | 12,147 (90.98%) | 1,205 (9.02%) | <0.001 |
| N1 | 8,084(92.15%) | 689 (7.85%) | |
| N2 | 1,227(93.38%) | 87 (6.62%) | |
| N3 | 212 (88.70%) | 27 (11.30%) | |
| Tumor Grade | |||
| Well Differentiated | 2,078(93.06%) | 155 (6.94%) | <0.001 |
| Moderately Differentiated | 9,647(91.69%) | 874(8.31%) | |
| Poorly Differentiated | 9,929 (88.22%) | 1,326(11.78%) | |
| Undifferentiated | 377 (88.92%) | 47 (11.08%) | |
| Tumor Size3 | |||
| ≤2.0 | 6,244 (92.34%) | 518(7.66%) | <0.001 |
| 2.1–4.0 | 6,289 (90.49%) | 661 (9.51%) | |
| 4.1–6.0 | 4,016(89.01%) | 496(10.99%) | |
| >6.0 | 2,545 (86.27%) | 405(13.73%) | |
| Neoadjuvant Therapy | |||
| No | 11,768 (86.93%) | 1,769(13.07%) | <0.001 |
| Yes | 15,156 (93.73%) | 1,013 (6.27%) | |
| Surgical Approacha | |||
| Open | 7,021 (92.88%) | 538 (7.12%) | <0.001 |
| Laparoscopic | 4,064 (87.93%) | 558(12.07%) | |
| Robotic | 828 (96.28%) | 32 (3.72%) | |
| Mean Annual Hospital Esophagectomy Volume Quartile (n/year) | |||
| 1 (≤2) | 6,684(88.61%) | 859(11.39%) | <0.001 |
| 2 (2.1–5.4) | 6,679(90.18%) | 727 (9.82%) | |
| 3(5.5–13.3) | 6,746(91.55%) | 623 (8.45%) | |
| 4 (>13.3) | 6,807 (92.24%) | 573.76%) | |
chi2 test
cm = centimeter
a
surgical approach available beginning in 2010